ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer

  • November 17, 2026

Share

Objective:

The article examines the objective, findings, and clinical context described in ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer.

Key Findings:
  • Among patients with advanced kidney cancer receiving immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors.
  • No KIM-1 drop was linked to immune-depleted tumors.
Interpretation:

The context reports an association between KIM-1 changes and tumor immune status; it provides no further interpretation.

Limitations:
  • The context does not provide study methods, sample size, numerical results, or additional details.

Original Source(s)

Related Content